Earnings

Today
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Earnings
Verb Technology reports Q1 EPS (16c), consensus (13c) » 14:55
05/13/21
05/13
14:55
05/13/21
14:55
VERB

Verb Technology

$1.04 /

+0.04 (+4.00%)

Reports Q1 revenue…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
VERB Verb Technology
$1.04 /

+0.04 (+4.00%)

VERB Verb Technology
$1.04 /

+0.04 (+4.00%)

01/13/21 Alliance Global Partners
Verb Technology price target raised to $2.75 from $2 at Alliance Global Partners
12/14/20
Fly Intel: Top five analyst initiations
12/14/20 Ladenburg
Verb Technology initiated with a Buy at Ladenburg
07/13/20 Alliance Global Partners
Alliance Global Partners keeps a Buy rating on VERB after preliminary results
VERB Verb Technology
$1.04 /

+0.04 (+4.00%)

  • 22
    Jul
  • 07
    Jul
Earnings
Stanley Black & Decker backs FY21 adjusted EPS view $10.70-$11.00 » 14:33
05/13/21
05/13
14:33
05/13/21
14:33
SWK

Stanley Black & Decker

$213.96 /

+4 (+1.91%)

Consensus $11.09.…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
SWK Stanley Black & Decker
$213.96 /

+4 (+1.91%)

SWK Stanley Black & Decker
$213.96 /

+4 (+1.91%)

04/13/21 Deutsche Bank
Stanley Black & Decker price target raised to $221 from $215 at Deutsche Bank
04/07/21 JPMorgan
Stanley Black & Decker price target raised to $206 from $200 at JPMorgan
04/06/21 Barclays
Stanley Black & Decker price target raised to $219 from $214 at Barclays
03/12/21
Fly Intel: Top five analyst upgrades
SWK Stanley Black & Decker
$213.96 /

+4 (+1.91%)

SWK Stanley Black & Decker
$213.96 /

+4 (+1.91%)

SWK Stanley Black & Decker
$213.96 /

+4 (+1.91%)

Earnings
Notable companies reporting after market close » 13:14
05/13/21
05/13
13:14
05/13/21
13:14
DIS

Disney

$178.22 /

+0.365 (+0.21%)

, ABNB

Airbnb

$134.31 /

-5.86 (-4.18%)

, COIN

Coinbase

$263.61 /

-19.99 (-7.05%)

, DASH

DoorDash

$111.36 /

-1.62 (-1.43%)

, GDRX

GoodRx

$28.35 /

-1.13 (-3.83%)

Notable companies…

Notable companies reporting after the market close, with earnings consensus, include Walt Disney (DIS), consensus 27c... Airbnb (ABNB), consensus ($1.19)... Coinbase (COIN), consensus $3.09... DoorDash (DASH), consensus (26c)... GoodRx (GDRX), consensus 7c.

ShowHide Related Items >><<
GDRX GoodRx
$28.35 /

-1.13 (-3.83%)

DIS Disney
$178.22 /

+0.365 (+0.21%)

DASH DoorDash
$111.36 /

-1.62 (-1.43%)

COIN Coinbase
$263.61 /

-19.99 (-7.05%)

ABNB Airbnb
$134.31 /

-5.86 (-4.18%)

DIS Disney
$178.22 /

+0.365 (+0.21%)

05/12/21 Morgan Stanley
Disney price target raised to $210 from $200 at Morgan Stanley
05/10/21 Evercore ISI
American Campus upgraded to Outperform at Evercore ISI on faster Disney ramp
05/03/21 BofA
BofA adds Disney and Avalara, removes Comcast and Netflix from U.S. 1 List
04/26/21 Truist
Disney could be beneficiary if Roku stops carrying YouTube TV, says Truist
ABNB Airbnb
$134.31 /

-5.86 (-4.18%)

04/26/21 Needham
Airbnb initiated with a Buy at Needham
04/05/21 Evercore ISI
Airbnb initiated with an Outperform at Evercore ISI
03/31/21 Wolfe Research
Airbnb assumed with a Peer Perform at Wolfe Research
03/10/21 Citi
Airbnb resumed with a Neutral at Citi
COIN Coinbase
$263.61 /

-19.99 (-7.05%)

09:53 Today
Fly Intel: Top five analyst initiations
06:02 Today Compass Point
Coinbase initiated with a Neutral at Compass Point
05/10/21 Oppenheimer
Oppenheimer starts Coinbase at Outperform with $434 price target
05/10/21 Oppenheimer
Coinbase initiated with an Outperform at Oppenheimer
DASH DoorDash
$111.36 /

-1.62 (-1.43%)

05/05/21 Cowen
Department of Labor comments incrementally encouraging for Uber/Lyft, says Cowen
04/26/21 Needham
DoorDash initiated with a Buy at Needham
04/23/21 JPMorgan
Olo agreement with DoorDash removes litigation risk, says JPMorgan
04/05/21 Evercore ISI
DoorDash initiated with an In Line at Evercore ISI
GDRX GoodRx
$28.35 /

-1.13 (-3.83%)

05/12/21 SVB Leerink
GoodRx moat still intact as Amazon Pharmacy push continues, says SVB Leerink
05/10/21 Cowen
GoodRx price target lowered to $58 from $70 at Cowen
04/05/21 Evercore ISI
GoodRx assumed with an Outperform at Evercore ISI
03/12/21 Barclays
GoodRx price target raised to $43 from $35 at Barclays
GDRX GoodRx
$28.35 /

-1.13 (-3.83%)

DIS Disney
$178.22 /

+0.365 (+0.21%)

DASH DoorDash
$111.36 /

-1.62 (-1.43%)

COIN Coinbase
$263.61 /

-19.99 (-7.05%)

ABNB Airbnb
$134.31 /

-5.86 (-4.18%)

  • 14
    Apr
  • 10
    Dec
  • 09
    Dec
  • 23
    Sep
GDRX GoodRx
$28.35 /

-1.13 (-3.83%)

DIS Disney
$178.22 /

+0.365 (+0.21%)

DASH DoorDash
$111.36 /

-1.62 (-1.43%)

COIN Coinbase
$263.61 /

-19.99 (-7.05%)

ABNB Airbnb
$134.31 /

-5.86 (-4.18%)

GDRX GoodRx
$28.35 /

-1.13 (-3.83%)

DIS Disney
$178.22 /

+0.365 (+0.21%)

DASH DoorDash
$111.36 /

-1.62 (-1.43%)

COIN Coinbase
$263.61 /

-19.99 (-7.05%)

ABNB Airbnb
$134.31 /

-5.86 (-4.18%)

GDRX GoodRx
$28.35 /

-1.13 (-3.83%)

DIS Disney
$178.22 /

+0.365 (+0.21%)

DASH DoorDash
$111.36 /

-1.62 (-1.43%)

COIN Coinbase
$263.61 /

-19.99 (-7.05%)

ABNB Airbnb
$134.31 /

-5.86 (-4.18%)

Earnings
Vallon Pharmaceuticals reports Q1 net loss $2.6M » 09:19
05/13/21
05/13
09:19
05/13/21
09:19
VLON

Vallon Pharmaceuticals

$3.81 /

-0.23 (-5.69%)

David Baker, President…

David Baker, President & Chief Executive Officer of Vallon commented, "The first quarter was marked by our successful IPO and continued execution on the clinical and operational fronts. The SEAL Study, our pivotal intranasal abuse study of our lead program, ADAIR, continues to progress well through enrollment and we remain on track to report data in the second half of this year, with an NDA submission targeted for the second quarter of 2022. We also made key appointments to our Board and executive leadership team in the first quarter that provide additional expertise and leadership as we advance our novel platform technology and development pipeline. Our team is committed to bringing this important program across the finish line and potentially bringing to market a new effective, abuse-deterrent treatment for ADHD."

ShowHide Related Items >><<
VLON Vallon Pharmaceuticals
$3.81 /

-0.23 (-5.69%)

  • 10
    Feb
VLON Vallon Pharmaceuticals
$3.81 /

-0.23 (-5.69%)

Earnings
ClearOne reports Q1 adjusted EPS (6c) vs. (9c) last year » 09:18
05/13/21
05/13
09:18
05/13/21
09:18
CLRO

ClearOne

$2.48 /

-0.07 (-2.75%)

Reports Q1 revenue $7.04M…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
CLRO ClearOne
$2.48 /

-0.07 (-2.75%)

CLRO ClearOne
$2.48 /

-0.07 (-2.75%)

Earnings
Tecogen reports Q1 EPS 7c, one est. (3c) » 09:11
05/13/21
05/13
09:11
05/13/21
09:11
TGEN

Tecogen

$1.66 /

-0.04 (-2.35%)

Reports Q1 revenue…

Reports Q1 revenue $6.06M, one est. $7.13M. "The first quarter saw the continued impact of COVID-19 on our core business areas. Despite the challenging economic environment, we saw significant improvements in our gross margin and further reductions in our operating expenses," commented Benjamin Locke, Tecogen Chief Executive Officer. "Product sales were down for the quarter but are expected to rebound as we move further into 2021. Our energy production assets are gradually returning to operation as COVID related closures and restrictions are eased, and our service maintenance revenues continue to grow each quarter. We are confident we will continue to see growth in our core business as we strive for profitability in 2021. I invite investors to read our shareholders letter on our website that provides more color on our vision for growth and establishing profitability from operations."

ShowHide Related Items >><<
TGEN Tecogen
$1.66 /

-0.04 (-2.35%)

TGEN Tecogen
$1.66 /

-0.04 (-2.35%)

Earnings
BioCardia reports Q1 EPS (18c), two est. (24c) » 08:53
05/13/21
05/13
08:53
05/13/21
08:53
BCDA

BioCardia

$3.33 /

-0.02 (-0.60%)

Reports Q1 revenue $0,…

Reports Q1 revenue $0, two est. $30,000. "We continue to make progress across our autologous and allogeneic cell therapy platforms and pipeline, targeting cardiovascular and pulmonary disease," said Peter Altman, Ph.D., BioCardia's Chief Executive Officer and President. "Our team is focused on accelerating clinical enrollment and expansion of our CardiAMP autologous cell therapy in both the heart failure and chronic myocardial ischemia indications with clinical partners in the U.S., Canada, and Japan. We are also working towards the acceptance of INDs for our allogeneic cell therapy product candidates for cardiac and pulmonary disease indications."

ShowHide Related Items >><<
BCDA BioCardia
$3.33 /

-0.02 (-0.60%)

BCDA BioCardia
$3.33 /

-0.02 (-0.60%)

04/16/21 Dawson James
Dawson James downgrades BioCardia, sees capital raise this year
04/16/21 Dawson James
BioCardia downgraded to Neutral from Buy at Dawson James
09/21/20
Fly Intel: Top five analyst initiations
09/21/20 Alliance Global Partners
BioCardia initiated with a Buy at Alliance Global Partners
BCDA BioCardia
$3.33 /

-0.02 (-0.60%)

BCDA BioCardia
$3.33 /

-0.02 (-0.60%)

Earnings
SPAR Group not issuing revenue, earnings guidance at this time » 08:51
05/13/21
05/13
08:51
05/13/21
08:51
SGRP

SPAR Group

$1.71 /

+0.01 (+0.59%)

Due to expectations of…

Due to expectations of continued volatility and uncertainty related to the COVID-19 pandemic and other macroeconomic factors, the Company is not issuing revenue and earnings guidance at this time. For 2021, the Company plans to continue to focus on growth of the core business, expanding internationally, innovating with technology and introducing new services

ShowHide Related Items >><<
SGRP SPAR Group
$1.71 /

+0.01 (+0.59%)

SGRP SPAR Group
$1.71 /

+0.01 (+0.59%)

Earnings
SPAR Group reports Q1 EPS 4c vs. 1c last year » 08:50
05/13/21
05/13
08:50
05/13/21
08:50
SGRP

SPAR Group

$1.71 /

+0.01 (+0.59%)

Reports Q1 revenue $61.1M…

Reports Q1 revenue $61.1M vs. $61.3M last year. "This past quarter was our highest first quarter net income performance in more than 15 years. Despite the lingering effects of the pandemic-led economic downturn, this also marks the third consecutive quarter of year-over-year improvements in net income. With a renewed energy, we have improved total company profitability, while realizing growth in several of our businesses such as Canada, Mexico, China and South Africa," stated Mike Matacunas, President and Chief Executive Officer. "Overall, 2021 is off to a solid start driven by new business while maintaining focus on the safety and well-being of our employees and clients."

ShowHide Related Items >><<
SGRP SPAR Group
$1.71 /

+0.01 (+0.59%)

SGRP SPAR Group
$1.71 /

+0.01 (+0.59%)

Earnings
Evaxion Biotech reports Q1 EPS (23c), two est. (30c) » 08:48
05/13/21
05/13
08:48
05/13/21
08:48
EVAX

Evaxion Biotech

$5.45 /

-0.57 (-9.47%)

Lars Wegner, CEO of…

Lars Wegner, CEO of Evaxion, said: "Evaxion made strong progress in Q1 2021, successfully concluding our U.S. IPO and continuing to advance our clinical programs. Our two lead product candidates, EVX-01 and EVX-02, are on track for results from Phase 1/2a trials late in Q2 and we continue to develop our RAVEN AI platform for vaccine design and development for viral infections. We believe that our cash reserves of $27 million provide a solid financial foundation and will facilitate the continued development of our four lead programs."

ShowHide Related Items >><<
EVAX Evaxion Biotech
$5.45 /

-0.57 (-9.47%)

EVAX Evaxion Biotech
$5.45 /

-0.57 (-9.47%)

03/02/21 Ladenburg
Evaxion Biotech initiated with a Buy, $23 target at Ladenburg
03/02/21 Oppenheimer
Evaxion Biotech initiated with an Outperform at Oppenheimer
03/02/21 Ladenburg
Evaxion Biotech initiated with a Buy at Ladenburg
EVAX Evaxion Biotech
$5.45 /

-0.57 (-9.47%)

  • 05
    Feb
EVAX Evaxion Biotech
$5.45 /

-0.57 (-9.47%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.